T1	Participants 92 121	patients with Crohn's disease
T2	Participants 373 597	consecutive patients from 17 centres in Australia and New Zealand undergoing intestinal resection of all macroscopic Crohn's disease, with an endoscopically accessible anastomosis, received 3 months of metronidazole therapy.
T3	Participants 598 715	Patients at high risk of recurrence also received a thiopurine, or adalimumab if they were intolerant to thiopurines.
T4	Participants 1631 1647	groups) patients
T5	Participants 1708 1748	Of 122 patients in the active care group
